Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of equecabtagene autoleucel versus standard therapy in lenalidomide-refractory relapsed/refractory multiple myeloma
CTR20241656Phase 3Active
- Sponsor
- Reindeer Biotech
- Start
- Jun 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of equecabtagene autoleucel in multiple myeloma (MM), sponsored by Reindeer Biotech. Started Jun 2024; status: active.
02
Drugs
equecabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20241656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241656.